BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Kura Oncology, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2024-11-14 4:32 pm Sale | 2024-09-30 | 13G | Kura Oncology, Inc. KURA | BIOTECHNOLOGY VALUE FUND L P | 4,212,346 5.400% | -3,160,882 (-42.87%) | Filing |
2024-02-14 09:39 am Purchase | 2023-12-31 | 13G | Kura Oncology, Inc. KURA | BIOTECHNOLOGY VALUE FUND L P | 7,373,228 9.900% | 3,572,245 (+93.98%) | Filing |
2023-02-13 6:17 pm Purchase | 2022-12-31 | 13G | Kura Oncology, Inc. KURA | BIOTECHNOLOGY VALUE FUND L P | 3,800,983 5.700% | 253,900 (+7.16%) | Filing |
2022-12-05 4:45 pm Purchase | 2022-11-23 | 13G | Kura Oncology, Inc. KURA | BIOTECHNOLOGY VALUE FUND L P | 3,547,083 5.300% | 2,301,171 (+184.70%) | Filing |
2021-02-11 4:59 pm Sale | 2020-12-31 | 13G | Kura Oncology, Inc. KURA | BIOTECHNOLOGY VALUE FUND L P | 1,245,912 1.900% | -1,188,784 (-48.83%) | Filing |
2020-03-16 5:23 pm Purchase | 2020-03-06 | 13G | Kura Oncology, Inc. KURA | BIOTECHNOLOGY VALUE FUND L P | 2,434,696 5.400% | 436,420 (+21.84%) | Filing |
2020-02-14 2:33 pm Sale | 2019-12-31 | 13G | Kura Oncology, Inc. KURA | BIOTECHNOLOGY VALUE FUND L P | 1,998,276 4.400% | -776,880 (-27.99%) | Filing |